Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00074828
Status:
COMPLETED
Last Update Posted:
2008-03-31
First Post:
2003-12-19
Brief Title:
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Comparison of the Oral Anticoagulant LY517717 Difumarate to Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolic Events VTE Post-Total Hip Replacement THR and Post-Total Knee Replacement TKR Surgery
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
LY517717 a capsule given by mouth is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs Leg and lung blood clots occur commonly after patients have surgery to replace a hip or knee joint These clots often occur while patients are in bed in the hospital after hip or knee joint surgery The purpose of this study is to test if different dose strengths amount of drug in the capsules of LY517717 can prevent blood clots from forming and to determine if LY517717 is safe This study will compare LY517717 to enoxaparin another blood thinner Enoxaparin is one of the standard medications given after hip or knee joint surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H8G-MC-EPBB | None | None | None |